Ignite Creation Date:
2024-05-06 @ 7:45 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06125457
Status:
RECRUITING
Last Update Posted:
2023-12-19
First Post:
2022-09-01
Brief Title:
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission
Sponsor:
University Hospital Strasbourg France
Organization:
University Hospital Strasbourg France
Study Overview
Official Title:
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission A Retrospective Cohort Study in Strasbourg University Hospital
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EpIgA
Brief Summary:
The management of patients with a selective IgA deficiency currently consists of symptomatic treatment with treatment of infections by occasional or prolonged antibiotic therapy immunosuppressive treatments for autoimmune pathologies symptomatic treatment of allergic manifestations
IVIG supplements are sometimes proposed in the event of recurrent infections and the demonstration of deficiencies in IgG subclasses IgG1 2 3 often not sought for diagnosis The factors associated with the severity of clinical manifestations are not well identified and patients with IgA deficiency must be monitored over the long term because of the risk of the appearance of autoimmune manifestations and neoplasia The identification of such factors could lead to the proposal of close monitoring for these patients
IgA deficiency which is frequent has not been identified as a risk factor for severe COVID-19 infection probably due to a lack of studies with sufficient recruitment The therapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19 infection is therefore not consensual
There is currently no action to be taken regarding the risk of transmission of IgA deficiency
IVIG supplements are sometimes proposed in the event of recurrent infections and the demonstration of deficiencies in IgG subclasses IgG1 2 3 often not sought for diagnosis The factors associated with the severity of clinical manifestations are not well identified and patients with IgA deficiency must be monitored over the long term because of the risk of the appearance of autoimmune manifestations and neoplasia The identification of such factors could lead to the proposal of close monitoring for these patients
IgA deficiency which is frequent has not been identified as a risk factor for severe COVID-19 infection probably due to a lack of studies with sufficient recruitment The therapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19 infection is therefore not consensual
There is currently no action to be taken regarding the risk of transmission of IgA deficiency
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None